• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

日常临床实践中的非酒精性脂肪性肝病：从诊断到治疗

Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy.

作者信息

Kosmalski Marcin, Mokros Łukasz

机构信息

Department of Clinical Pharmacology, Medical University of Lodz, 90-153 Lodz, Poland.

Department of Child and Adolescent Psychiatry, Medical University of Lodz, 92-213 Lodz, Poland.

出版信息

Life (Basel). 2025 Feb 25;15(3):363. doi: 10.3390/life15030363.

DOI:10.3390/life15030363
PMID:40141708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11943963/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently one of the most common hepatic disorders observed in daily medical practice [...].

摘要

非酒精性脂肪性肝病（NAFLD）是目前日常医疗实践中观察到的最常见的肝脏疾病之一[...]。

相似文献

1
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy.日常临床实践中的非酒精性脂肪性肝病：从诊断到治疗
Life (Basel). 2025 Feb 25;15(3):363. doi: 10.3390/life15030363.
2
Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中纤维化的无创诊断
J Clin Exp Hepatol. 2012 Jun;2(2):145-55. doi: 10.1016/S0973-6883(12)60103-0. Epub 2012 Jul 21.
3
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用，或与吡格列酮及其他药物联合使用，用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
4
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.富含半胱氨酸的酸性分泌蛋白相关模块化钙结合蛋白2在星状细胞中的表达与人类非酒精性脂肪性肝病的严重程度相关。
JHEP Rep. 2022 Oct 28;5(2):100615. doi: 10.1016/j.jhepr.2022.100615. eCollection 2023 Feb.
5
Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.非酒精性脂肪性肝病患者的患者报告结局：慢性肝病问卷-非酒精性脂肪性肝病/非酒精性脂肪性肝炎的叙述性综述
J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul 16.
6
Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.水脂 MRI 和质子 MRS 对非酒精性脂肪性肝病患者肝脂肪和肝脂肪及铁异质性分布评估的验证。
Eur J Radiol. 2018 Oct;107:7-13. doi: 10.1016/j.ejrad.2018.08.008. Epub 2018 Aug 11.
7
Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的诊断与分类：当前概念与尚存挑战
Hepatol Res. 2015 Jan;45(1):20-8. doi: 10.1111/hepr.12333. Epub 2014 May 20.
8
Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.G 蛋白偶联受体在肝星状细胞中的作用及非酒精性脂肪性肝病抗纤维化治疗的方法。
Front Endocrinol (Lausanne). 2021 Dec 6;12:773432. doi: 10.3389/fendo.2021.773432. eCollection 2021.
9
Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province.伊斯法罕省非酒精性脂肪性肝病患者肝纤维化评估临床实践指南的适应性调整
Int J Prev Med. 2024 Aug 5;15:27. doi: 10.4103/ijpvm.ijpvm_284_22. eCollection 2024.
10
MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.非酒精性脂肪性肝病中的 microRNAs：进展与展望。
Mol Metab. 2022 Nov;65:101581. doi: 10.1016/j.molmet.2022.101581. Epub 2022 Aug 23.

引用本文的文献

1
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease.营养素作为代谢功能障碍相关脂肪性肝病中的表观遗传调节剂。
World J Hepatol. 2025 Aug 27;17(8):108182. doi: 10.4254/wjh.v17.i8.108182.
2
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.

本文引用的文献

1
Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?肌少症作为非酒精性脂肪性肝病（NAFLD）患者死亡的危险因素：我们应如何诊断？
J Dig Dis. 2024 Nov-Dec;25(11-12):645-654. doi: 10.1111/1751-2980.13329. Epub 2025 Feb 2.
2
Inflammatory biomarkers as cost-effective predictive tools in metabolic dysfunction-associated fatty liver disease.炎症生物标志物作为代谢功能障碍相关脂肪性肝病中具有成本效益的预测工具。
World J Gastroenterol. 2024 Dec 21;30(47):5086-5091. doi: 10.3748/wjg.v30.i47.5086.
3
MASLD: predictive value for liver-related events and extra-hepatic complications.代谢相关脂肪性肝病（MASLD）：对肝脏相关事件和肝外并发症的预测价值
Expert Rev Gastroenterol Hepatol. 2024 Nov;18(11):685-688. doi: 10.1080/17474124.2024.2435504. Epub 2024 Dec 1.
4
Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries.全球非酒精性脂肪性肝病患病率：一项包含 38 个国家 7800 万人的更新综述荟萃分析。
Arch Med Res. 2024 Sep;55(6):103043. doi: 10.1016/j.arcmed.2024.103043. Epub 2024 Aug 1.
5
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).探索代谢功能障碍相关脂肪性肝病（MASLD）的多种治疗策略。
Life (Basel). 2024 Jul 3;14(7):844. doi: 10.3390/life14070844.
6
Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.代谢功能障碍相关脂肪性肝病：从发病机制到当前治疗选择。
Int J Mol Sci. 2024 May 22;25(11):5640. doi: 10.3390/ijms25115640.
7
Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.炎症标志物作为代谢功能障碍相关脂肪性肝病的诊断和精准营养工具：来自肥胖相关性脂肪肝试验的结果。
Clin Nutr. 2024 Jul;43(7):1770-1781. doi: 10.1016/j.clnu.2024.05.042. Epub 2024 May 31.
8
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
9
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.代谢相关脂肪性肝病时代非侵入性评分和血清生物标志物在脂肪性肝病中的应用：从非酒精性脂肪性肝病到代谢相关脂肪性肝病和脂肪性肝病的综合评价。
Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29.
10
Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis.非酒精性脂肪性肝病与肌少症风险的关联：系统评价和荟萃分析。
BMJ Open. 2024 May 6;14(5):e078933. doi: 10.1136/bmjopen-2023-078933.